文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

CYP2B6基因型与多替拉韦和依非韦伦体重增加的差异

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究基于ADVANCE试验中随机接受依非韦伦/恩曲他滨/替诺福韦DF或多替拉韦/恩曲他滨/替诺福韦DF的初治HIV感染者,比较CYP2B6代谢基因型与48周体重及区域脂肪变化的关系。

要点

  • 依非韦伦组CYP2B6代谢基因型与48周体重增加相关,快代谢者增加最多。
  • CYP2B6慢/中间代谢者体重增加受损可解释多替拉韦相比依非韦伦体重增加更多。

核心结论

  • CYP2B6代谢基因型与起始依非韦伦为基础ART的HIV感染者体重增加相关。
  • 依非韦伦组快代谢者与多替拉韦组体重增加相似,提示慢/中间代谢者体重增加受损可解释多替拉韦相比依非韦伦体重增加更多。

研究设计与样本

  • 来自ADVANCE研究的事后分析,纳入随机接受依非韦伦/恩曲他滨/替诺福韦DF或多替拉韦/恩曲他滨/替诺福韦DF的初治HIV感染者。
  • 多替拉韦组342例、依非韦伦组168例参与者同意基因分型。
  • 比较基线至第48周体重和DXA区域脂肪变化。

主要发现

  • 依非韦伦组CYP2B6代谢基因型与女性区域脂肪变化相关,与男性无关。
  • 所有参与者中与体重增加独立相关的变量包括基线CD4计数、基线HIV-1 RNA和CYP2B6代谢基因型。
  • 女性体重增加大于男性。

临床怎么用

  • 对于起始依非韦伦为基础ART的HIV感染者,CYP2B6代谢基因型可能有助于识别体重增加风险较高的快代谢者。
  • CYP2B6慢/中间代谢者使用依非韦伦时体重增加较少,转换或选择多替拉韦时需关注体重增加。

局限性

  • 本研究为ADVANCE研究的子研究,仅纳入同意基因分型的参与者。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir is associated with more weight gain than efavirenz. Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART). METHODS: We studied ART-naive participants from the ADVANCE study randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emtricitabine/TDF arms. We compared changes in weight and regional fat on DXA from baseline to week 48 between CYP2B6 metabolizer genotypes in the efavirenz arm, and with the dolutegravir arm. RESULTS: There were 342 participants in the dolutegravir arm and 168 in the efavirenz arm who consented to genotyping. Baseline characteristics were similar. Weight gain was greater in women than men. In the efavirenz arm CYP2B6 metaboliser genotype was associated with weight gain (P = .009), with extensive metabolizers gaining the most weight, and with changes in regional fat in women, but not in men. Weight gain was similar in CYP2B6 extensive metabolizers in the efavirenz arm and in the dolutegravir arm (P = .836). The following variables were independently associated with weight gain in all participants: baseline CD4 count, baseline human immunodeficiency virus type 1 (HIV-1) RNA, and CYP2B6 metaboliser genotype. CONCLUSIONS: CYP2B6 metaboliser genotype was associated with weight gain in PLWH starting efavirenz-based ART. Weight gain was similar between CYP2B6 extensive metabolizers in the efavirenz arm and in the dolutegravir arm, suggesting that impaired weight gain among CYP2B6 slow or intermediate metabolizers could explain the increased weight gain on dolutegravir compared with efavirenz observed in ADVANCE and other studies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Griesel R, Maartens G, Chirehwa M, et al. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021. PMID: 32960272. doi:10.1093/cid/ciaa1073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。